Location out of bounds


Resources for journalists

All Press Releases

BloodCenter of Wisconsin launches breakthrough FDA approved leukemia test

Milwaukee – August 29, 2017

BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, is the first to offer testing using Abbott Laboratories’ RealTime IDH2 assay that identifies specific gene mutations in patients with acute myeloid leukemia (AML). BloodCenter’s breakthrough offering, which follows Abbott’s recent approval from the U.S. Food and Drug Administration, helps to deliver new and more effective treatments to patients with relapsed and refractory AML.

BloodCenter’s test, IDH2 Abbott RealTime PCR, is more sensitive to detecting the IDH2 genetic mutation found in patients’ blood and bone marrow samples. The method detects single nucleotide variants (SNVs) coding nine IDH2 R140 and R172 mutations in patients’ DNA. With a five-day turnaround time, this test helps identify AML patients that could benefit from new treatments, including the recently FDA approved drug called IDHIFA®.

According to the National Cancer Institute, more than 21,000 people will be diagnosed with AML this year and more than 10,000 patients will die due to the disease. Between 8 percent and 19 percent of AML patients have IDH2 mutations.

"This new test is an exciting addition to BloodCenter’s molecular oncology diagnostics portfolio. Through our collaboration with Abbott, we can continue to help provide better treatment options and outcomes for AML patients,” said Dr. Matthew Anderson, M.D., Ph.D., VP and medical director of the Diagnostic Laboratories at BloodCenter of Wisconsin. “This test will help physicians to provide more customized treatment for patients, and is another example of how BloodCenter is advancing precision medicine in our areas of expertise."


Contact Us

Fay Spano

Director, Public Relations and Corporate Communications
Email (414) 937-6124

Other Press Releases


BloodCenter of Wisconsin launches new educational webinar series

March 7, 2018

Industry thought leaders to discuss topics including transfusion medicine and hematology

Read More
Dr. Gottschall being interviewed

BloodCenter of Wisconsin presents at Thrombosis & Hemostasis Societies of North America 2018 Summit

February 26, 2018

BloodCenter of Wisconsin, will offer 10 unique presentations, posters and short group discussions.

Read More
Technician inspecting bags of pathogen reduced platelets.

Versiti among first in U.S. to offer pathogen reduced platelets

February 21, 2018

Versiti, Inc., a national leader in blood health innovation, is among the first in the United States to provide pathogen reduced platelets.

Read More

This website uses cookies to ensure you get the best experience on our website. Learn more